Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation.

Blood - 1 Jun 2007

French Ruth R, Taraban Vadim Y, Crowther Graham R, Rowley Tania F, Gray Juliet C, Johnson Peter W, Tutt Alison L, Al-Shamkhani Aymen, Glennie Martin J

Abstract excerpt

Growing evidence points to the potential of agonistic anti-CD40 mAbs as adjuvants for vaccination against cancer. These appear to act by maturing dendritic cells (DCs) and allowing them to prime CD8 cytotoxic T lymphocytes (CTLs). Although it is well established that optimal T-cell priming requir...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to CD40 Antigens
Share to CD8-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dendritic Cells

Share to Immunotherapy

Share to Lymphoma

Share to Spleen

Share to Tumor Necrosis Factor Receptor Superfamily, Member 7

Source

Identifiers

PMID: 17311995
DOI: 10.1182/blood-2006-11-057216

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-17311995-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation.PMID 17311995Read ↗

PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+ T-Cell–Driven Antitumor ImmunitySemantic proximity Read ↗

CSF-1R–Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after ChemotherapySemantic proximity Read ↗

B7-CTLA4 interaction promotes cognate destruction of tumor cells by cytotoxic T lymphocytes in vivo.Semantic proximity Read ↗

Deciphering CD137 (4‐1BB) signaling in T‐cell costimulation for translation into successful cancer immunotherapySemantic proximity Read ↗

Agonistic anti-CD40 converts Tregs into Type 1 effectors within the tumor micro-environmentSemantic proximity Read ↗

Accumulation of Memory Precursor CD8 T Cells in Regressing Tumors following Combination Therapy with Vaccine and Anti-PD-1 AntibodySemantic proximity Read ↗

CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo.Semantic proximity Read ↗

Cell targeting and immunostimulatory properties of a novel Fcγ-receptor independent agonistic anti-CD40 antibody in rhesus macaquesSemantic proximity Read ↗

Rapid deletion and inactivation of CTLs upon recognition of a number of target cells over a critical threshold.Semantic proximity Read ↗

Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies.Semantic proximity Read ↗

The human CD40 agonistic antibody ADC-1013 generates immune mediated anti-tumor effects in syngeneic tumor models in hCD40 transgenic miceSemantic proximity Read ↗

CD40 and CD70 co-stimulate a potent in vivo antitumor T cell response.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.